Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been approved for 1.5 AMA PRA Category 1 Credits™.
Acknowledgment of Commercial Support
This activity is supported by an educational grantfrom Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
Cases & Conversations™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing CV Events and Patient Hospitalizations with COVID-19 Considerations
Friday, April 30, 2021
Live, Interactive Virtual Conference!
4:30 PM - 6:30 PM EST
Although impaired glucose metabolism has a central role in the pathology of cardiovascular (CV) complications in individuals with type 2 diabetes (T2D), several studies have demonstrated that CV risk cannot necessarily be reduced by achieving a normal serum glucose goal. Recent trials have provided valuable insights concerning the CV benefits of some anti-diabetes medications, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. In fact, the American Diabetes Association now recommends that, in addition to metformin, patients with T2D and established atherosclerotic cardiovascular disease should receive a glucose-lowering drug shown to reduce major CV events. Importantly, a comprehensive medical approach against multifactorial pathologies in T2D such as insulin resistance, obesity, hypertension, and dyslipidemia, in addition to lifestyle therapies, should be routinely performed in the clinical setting.
A panel of experts in T2D and reducing CV risk will discuss the latest clinical trial findings and guideline recommendations for patients with T2D and CV disease. Using patient case examples, these experts will present the most recent evidence for developing a comprehensive medical approach for these patients, and what this approach looks like in clinical practice.
Benefits of Attending
- Understand the latest treatment guidelines for patients with T2D
- Learn how to treat patients with T2D and CV disease
- Learn the role of newer treatment options in managing cases of T2D and CV disease
- Learn the real-world evidence regarding the efficacy and safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists
- Ensure the proper treatment of patients with T2D and CVD who contract coronavirus disease 2019 (COVID-19)
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
This educational program is directed toward all attendees of the 2021 ACP Internal Medicine Meeting. Primary care physicians, diabetologists, endocrinologists, cardiologists, certified diabetes educators, NPs, PAs and other HCPs who treat patients with T2D will be invited to participate in the online enduring program.
Upon completion of this activity, participants will be able to:
- Examine current treatment guidelines for patients with T2D for effective management of cardiovascular risk
- Evaluate the real-world evidence for reducing CV events and hospitalizations to improve outcomes for patients with T2D
- Apply emerging clinical data on issues in management of T2D in patients with COVID-19 toward the development of treatment plans
Medical Director / President
Louisville Metabolic and Atherosclerosis Research Center
Your Body Goal
Registration2 Ways to Register
- Online: click here.
- Phone: Please call (888) 949-0045 or (609) 378-3701
Physicians' Education Resource®
2 Clarke Drive
Cranbury, NJ 08512
Registration Fee - Free
For registration assistance, please email email@example.com, or call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.
Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.
By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
You must be logged in to PER to register for this meeting
Or Register for PER now